Abnormal expression of Nek2 and β-catenin in breast carcinoma: Clinicopathological correlations

Histopathology

Volumn 59, Issue 4, 2011, Pages 631-642

  Wang, Shuling ^a   Li, Weidong ^a   Lv, Shuhua ^a   Wang, Yahong ^a   Liu, Ziyu ^a   Zhang, Jing ^a   Liu, Tieju ^a   Niu, Yun ^a  

^a KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

Author keywords

catenin; Breast invasive ductal carcinoma; Ductal carcinoma insitu; Ki67; Nek2

Indexed keywords

BETA CATENIN; ESTROGEN RECEPTOR; KI 67 ANTIGEN; MESSENGER RNA; PROTEIN SERINE THREONINE KINASE; PROTEIN SERINE THREONINE KINASE NEK2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST; BREAST CARCINOMA; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; CYTOPLASM; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTRADUCTAL CARCINOMA; INVASIVE DUCTAL CARCINOMA; LYMPH NODE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BETA CATENIN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROTEIN-SERINE-THREONINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 80054962373     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.03941.x     Document Type: Article

References (29)

1. Wu W, Baxter JE, Wattam SL et al. Alternative splicing controls nuclear translocation of the cell cycle-regulated Nek2 kinase. J. Biol. Chem. 2007; 282; 26431-26440.
2. Bahmanyar S, Kaplan DD, Deluca JG et al. Beta-Catenin is a Nek2 substrate involved in centrosome separation. Genes Dev. 2008; 22; 91-105.
3. Huang P, Senga T, Hamaguchi M. A novel role of phospho-beta-catenin in microtubule regrowth at centrosome. Oncogene 2007; 26; 4357-4371.
4. Sankaran S, Parvin JD. Centrosome function in normal and tumor cells. J. Cell. Biochem. 2006; 99; 1240-1250.
5. Ganem NJ, Godinho SA, Pellman D. A mechanism linking extra centrosomes to chromosomal instability. Nature 2009; 460; 278-282.
6. Niu Y, Liu T, Tse GM et al. Increased expression of centrosomal alpha, gamma-tubulin in atypical ductal hyperplasia and carcinoma of the breast. Cancer Sci. 2009; 100; 580-587.
7. Tavassoli FA, Devilee P. Pathology and genetics of tumors of the breast and female genital organs. World Health Organization Classifi{ligature}cation of Tumors. Lyon: IARC Press, 2003.
8. Remmele W, Schicketanz KH. Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs. subjective grading (IRS). Pathol. Res. Pract. 1993; 189; 862-866.
9. Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol. 2010; 28; 2784-2795.
10. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 2007; 25; 118-145.
11. Rouzier R, Perou CM, Symmans WF et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res. 2005; 11; 5678-5685.
12. Rakha EA, Elsheikh SE, Aleskandarany MA et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin. Cancer Res. 2009; 15; 2302-2310.
13. Hayward DG, Newbatt Y, Pickard L et al. Identification by high-throughput screening of viridin analogs as biochemical and cell-based inhibitors of the cell cycle-regulated Nek2 kinase. J. Biomol. Screen. 2010; 15; 918-927.
14. Fry AM. The Nek2 protein kinase: a novel regulator of centrosome structure. Oncogene 2002; 21; 6184-6194.
15. Fletcher L, Cerniglia GJ, Nigg EA, Yend TJ, Muschel RJ. Inhibition of centrosome separation after DNA damage: a role for Nek2. Radiat. Res. 2004; 162; 128-135.
16. Hayward DG, Clarke RB, Faragher AJ, Pillai MR, Hagan IM, Fry AM. The centrosomal kinase Nek2 displays elevated levels of protein expression in human breast cancer. Cancer Res. 2004; 64; 7370-7376.
17. Hayward DG, Fry AM. Nek2 kinase in chromosome instability and cancer. Cancer Lett. 2006; 237; 155-166.
18. Rellos P, Ivins FJ, Baxter JE et al. Structure and regulation of the human Nek2 centrosomal kinase. J. Biol. Chem. 2007; 282; 6833-6842.
19. Liu Q, Hirohashi Y, Du X, Greene MI, Wang Q. Nek2 targets the mitotic checkpoint proteins Mad2 and Cdc20: a mechanism for aneuploidy in cancer. Exp. Mol. Pathol. 2010; 88; 225-233.
20. Tsunoda N, Kokuryo T, Oda K et al. Nek2 as a novel molecular target for the treatment of breast carcinoma. Cancer Sci. 2009; 100; 111-116.
21. Weinstein IB ed. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 2002; 297;63-64.
22. Westwood I, Cheary DM, Baxter JE et al. Insights into the conformational variability and regulation of human Nek2 kinase. J. Mol. Biol. 2009; 386; 476-485.
23. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004; 303; 1483-1487.
24. Sadot E, Conacci-Sorrell M, Zhurinsky J et al. Regulation of S33/S37 phosphorylated beta-catenin in normal and transformed cells. J. Cell Sci. 2002; 115; 2771-2780.
25. Ligon LA, Karki S, Tokito M, Holzbaur EL. Dynein binds to beta-catenin and may tether microtubules at adherens junctions. Nat. Cell Biol. 2001; 3; 913-917.
26. Hadjihannas MV, Bruckner M, Behrens J. Conductin/axin2 and Wnt signalling regulates centrosome cohesion. EMBO Rep. 2010; 11; 317-324.
27. Kumano G, Kawai N, Nishida H. Macho-1 regulates unequal cell divisions independently of its function as a muscle determinant. Dev. Biol. 2010; 344; 284-292.
28. Rassi H. Stem cell therapy for hereditary breast cancer. Tsitol. Genet. 2009; 43; 80-88.
29. Carey LA, Perou CM, Livasy CA et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295; 2492-2502.